Xilio Therapeutics (XLO) Change in Account Payables (2020 - 2026)
Xilio Therapeutics (XLO) reported Change in Account Payables of -$1.7 million for Q1 2026, down 184.75% on a YoY basis from $2.0 million in Q1 2025, and down 492.52% sequentially from $428000.0 in Q4 2025.
Xilio Therapeutics (XLO) Change in Account Payables (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Change in Account Payables data on file, last reported at -$1.7 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 184.75% year-over-year to -$1.7 million; the trailing twelve-month figure through Mar 2026 stood at -$938000.0 (down 175.58% YoY), and the FY2025 full-year result was $152000.0, down 90.04% from the prior year.
- Change in Account Payables eased to -$1.7 million in Q1 2026, from $428000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $2.1 million in Q2 2025 to a low of -$1.8 million in Q3 2025.
- A 5-year average of -$92941.2 and a median of -$305000.0 in 2024 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables jumped 465.75% in 2024 and sank 542.14% in 2025, its largest moves.
- Tracing XLO's Change in Account Payables over 5 years: stood at $1.5 million in 2022, then sank by 130.06% to -$438000.0 in 2023, then jumped by 465.75% to $1.6 million in 2024, then sank by 73.28% to $428000.0 in 2025, then sank by 492.52% to -$1.7 million in 2026.
- Business Quant data shows XLO's Change in Account Payables at -$1.7 million in Q1 2026, $428000.0 in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | - |
| 10 | Xilio Therapeutics | 145.98 Mn | -4.32 Mn | - | -1.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.68 Mn |
| Mar 31, 2026 | -1.68 Mn |
| Dec 31, 2025 | 428,000.00 |
| Dec 31, 2025 | 428,000.00 |
| Sep 30, 2025 | -1.80 Mn |
| Sep 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Mar 31, 2025 | -590,000.00 |
| Mar 31, 2025 | -590,000.00 |
| Dec 31, 2024 | 1.60 Mn |
| Dec 31, 2024 | 1.60 Mn |
| Sep 30, 2024 | -280,000.00 |
| Sep 30, 2024 | -280,000.00 |
| Jun 30, 2024 | 509,000.00 |
| Jun 30, 2024 | 509,000.00 |
| Mar 31, 2024 | -305,000.00 |
| Mar 31, 2024 | -305,000.00 |
| Dec 31, 2023 | -438,000.00 |
| Dec 31, 2023 | -438,000.00 |